June 14, 2023 Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
Read More
June 14, 2023 Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023
Read More
June 14, 2023 Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 13, 2023 Recommendation of Ryvu’s project for funding by the Medical Research Agency
Read More
June 9, 2023 Publication of the updated clinical and preclinical data on RVU120
Read More
May 26, 2023 Correction of the current report on the convening of the Company’s Annual General Meeting
Read More
May 25, 2023 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
May 25, 2023 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
May 25, 2023 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
May 25, 2023 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
May 23, 2023 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
May 18, 2023 Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
May 16, 2023 Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
Read More
May 16, 2023 Ryvu Therapeutics S.A. Q1 2023 Financial Report
Read More
May 11, 2023 New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress
Read More
May 5, 2023 Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank
Read More
April 20, 2023 Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS
Read More
April 12, 2023 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
April 6, 2023 Notice of termination regarding Option, License and Collaboration Agreement with Galapagos NV
Read More
March 10, 2023 Change of publication date of the annual report for 2022
Read More
Posts navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok Privacy policy